Oruka Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Oruka Therapeutics, Inc. (ORKA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $1.87 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2024-02-01
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2012-06-30 was $0.00, a 100.00% decline year-over-year.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2011-06-30 was $1.83.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $1.87, a 10.53% decline from fiscal 2021.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $2.09, a 36.28% decline from fiscal 2020.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $3.28.
- Oruka Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2018 was $9.34, a 483.75% increase from fiscal 2017.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|
| 2022-12-31 | $1.87 10-K · filed 2024-02-01 | ||||
| 2021-12-31 | $2.09 10-K · filed 2023-02-24 | ||||
| 2020-12-31 | $3.28 10-K · filed 2022-03-14 | ||||
| 2018-12-31 | $9.34 10-K · filed 2020-02-18 | $0.52 10-K · filed 2019-02-27 | |||
| 2017-12-31 | $1.60 10-K · filed 2019-02-27 | ||||
| 2016-12-31 | $2.01 10-K · filed 2018-03-22 | ||||
| 2015-12-31 | $3.57 10-K · filed 2017-03-21 | ||||
| 2014-12-31 | $9.58 10-K · filed 2016-03-17 | $1.37 10-K · filed 2015-03-19 | |||
| 2013-12-31 | $1.05 10-K · filed 2015-03-19 | ||||
| 2012-12-31 | $4.68 10-K · filed 2014-03-20 | ||||
| 2012-09-30 | $0.78 10-Q · filed 2012-11-13 | ||||
| 2012-06-30 | $0.00 10-Q · filed 2012-08-13 | $0.78 10-Q · filed 2012-08-13 | |||
| 2011-12-31 | $10.95 10-K · filed 2013-03-21 | ||||
| 2011-09-30 | $1.83 10-Q · filed 2012-11-13 | ||||
| 2011-06-30 | $1.83 10-Q · filed 2012-08-13 | $1.83 10-Q · filed 2012-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |